PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dornase alfa - Cystic fibrosis
PAD Profile : Dornase alfa - Cystic fibrosis Important
Brand Names Include :
Pulmozyme
Important Information :
NHSE Specialised Commissioned services only.
GPs may continue to prescribe for their EXISTING patients only. All new patients are commissioned by NHSE.
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Aztreonam
- Colistimethate sodium
- Ivacaftor
- Tobramycin
- Levofloxacin
- Amikacin
- Ciprofloxacin
- Lumacaftor/ivacaftor
- Mannitol
- Tezacaftor/ivacaftor
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
01 April 2013
Not Set
FOR NEW PATIENTS ONLY. Prescribing of Dornase Alfa will be considered RED on the Prescribing Adviisory database. Historically amber for Cystic Fibrosis patients via nebulisation / inhalation. Funding now rests with NHS England for this treatment.
FOR EXISTING PATIENTS: GPs should continue to prescribe these treatments. NHS England are looking to repatriate these patients in the future. The Medicines Management Team will be in contact with prescribers when they have more information
Associated BNF Codes
03. Respiratory System
03.07.00. Mucolytics